Ocrelizumab subcutaneous study in pediatric RRMS patients
Summary
The National Library of Medicine registered clinical trial NCT07503340 on ClinicalTrials.gov, a study evaluating subcutaneous ocrelizumab in pediatric patients with relapsing-remitting multiple sclerosis (RRMS). The trial is sponsored by Genentech, Inc. and will assess the safety and pharmacokinetics of a subcutaneous formulation in patients aged 10 to under 18 years.
What changed
Clinical trial NCT07503340 has been registered on ClinicalTrials.gov, documenting a Phase II/III study investigating a subcutaneous formulation of ocrelizumab for treating relapsing-remitting multiple sclerosis in pediatric patients aged 10 to under 18 years. The trial will evaluate safety, tolerability, and pharmacokinetics compared to the existing intravenous formulation.
Healthcare providers and clinical sites should note this registration for patient referral eligibility and recruitment. Parents or guardians of pediatric MS patients should consult their neurologists regarding potential trial participation. The trial registration satisfies FDA submission requirements for applicable clinical trials under 42 CFR Part 11.
Source document (simplified)
Show glossary
CFR references
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.